Orgenesis Inc. (NASDAQ:ORGS – Get Rating) shares fell 3.1% during mid-day trading on Friday . The stock traded as low as $1.22 and last traded at $1.23. 32,890 shares traded hands during mid-day trading, a decline of 40% from the average session volume of 55,123 shares. The stock had previously closed at $1.27.
Analysts Set New Price Targets
Separately, Benchmark reaffirmed a “buy” rating and issued a $6.00 price target on shares of Orgenesis in a report on Wednesday, March 22nd.
Orgenesis Stock Down 3.1 %
The firm has a market cap of $34.86 million, a price-to-earnings ratio of -2.46 and a beta of 0.93. The firm’s fifty day moving average is $1.17 and its two-hundred day moving average is $1.60. The company has a debt-to-equity ratio of 0.60, a current ratio of 3.55 and a quick ratio of 3.54.
Institutional Investors Weigh In On Orgenesis
A number of institutional investors and hedge funds have recently bought and sold shares of ORGS. Redmond Asset Management LLC acquired a new stake in Orgenesis in the 1st quarter valued at about $543,000. Chapin Davis Inc. acquired a new stake in Orgenesis in the 4th quarter valued at about $39,000. Dimensional Fund Advisors LP lifted its stake in Orgenesis by 49.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 36,409 shares of the company’s stock valued at $71,000 after buying an additional 12,000 shares in the last quarter. Geode Capital Management LLC lifted its stake in Orgenesis by 3.6% during the fourth quarter. Geode Capital Management LLC now owns 206,754 shares of the company’s stock valued at $403,000 after buying an additional 7,198 shares in the last quarter. Finally, State Street Corp lifted its stake in Orgenesis by 7.5% during the first quarter. State Street Corp now owns 88,659 shares of the company’s stock valued at $308,000 after buying an additional 6,159 shares in the last quarter. 15.16% of the stock is owned by institutional investors and hedge funds.
Orgenesis Company Profile
Orgenesis Inc, a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network.
Recommended Stories
- Get a free research report on Orgenesis from StockNews.com
- CarMax Stock Flying On Earnings Beat, Return Of The Highs?
- Commercial Metals Company Shakes Off The Rust: Confirms Uptrend
- Smith & Wesson, A Timeless Value Play At Decade Lows
- Wayfair: From Steep Decline to Recent Surge
- Five stocks we like better than Orgenesis
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
